{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:51:41Z","timestamp":1792601501297,"version":"4.5.0"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01795-9","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:49:25Z","timestamp":1752140965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["The AML immune paradox: decoding escape pathways and pioneering checkpoint, vaccine, and combination strategies"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-7613","authenticated-orcid":false,"given":"Hamed","family":"Soleimani Samarkhazan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7769-8320","authenticated-orcid":false,"given":"Fatemeh Sadat","family":"Shafiei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-6092","authenticated-orcid":false,"given":"Zahra","family":"Taghinejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4559-6525","authenticated-orcid":false,"given":"Mohsen","family":"Maleknia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9755-2850","authenticated-orcid":false,"given":"Hanieh","family":"Noormohamadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1029-751X","authenticated-orcid":false,"given":"Atieh","family":"Raoufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4863-2595","authenticated-orcid":false,"given":"Sina","family":"Nouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"issue":"4","key":"1795_CR1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347.","journal-title":"Blood"},{"issue":"3","key":"1795_CR2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.beha.2013.10.005","volume":"26","author":"F Ravandi","year":"2013","unstructured":"Ravandi F. Relapsed acute myeloid leukemia: why is there no standard of care? Best Pract Res Clin Haematol. 2013;26(3):253\u20139.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"3","key":"1795_CR3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","volume":"16","author":"JS O'Donnell","year":"2019","unstructured":"O\u2019Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16(3):151\u201367.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"1795_CR4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","volume":"21","author":"D Hanahan","year":"2012","unstructured":"Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309\u201322.","journal-title":"Cancer Cell"},{"key":"1795_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061423","author":"S Sendker","year":"2021","unstructured":"Sendker S, Reinhardt D, Niktoreh N. Redirecting the immune microenvironment in acute myeloid leukemia. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13061423.","journal-title":"Cancers (Basel)"},{"issue":"14","key":"1795_CR6","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2010-03-275446","volume":"116","author":"Q Zhou","year":"2010","unstructured":"Zhou Q, et al. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood. 2010;116(14):2484\u201393.","journal-title":"Blood"},{"issue":"5","key":"1795_CR7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00277-004-0978-0","volume":"84","author":"M Graf","year":"2005","unstructured":"Graf M, et al. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML). Ann Hematol. 2005;84(5):287\u201397.","journal-title":"Ann Hematol"},{"issue":"3","key":"1795_CR8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/14737140.2022.2030227","volume":"22","author":"JP Bewersdorf","year":"2022","unstructured":"Bewersdorf JP, Zeidan AM. Myeloid-derived suppressor cells: a grey eminence in the AML tumor microenvironment? Expert Rev Anticancer Ther. 2022;22(3):239\u201341.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"7","key":"1795_CR9","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/blood-2006-07-036863","volume":"109","author":"A Curti","year":"2007","unstructured":"Curti A, et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood. 2007;109(7):2871\u20137.","journal-title":"Blood"},{"key":"1795_CR10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13045-015-0189-2","volume":"8","author":"FM Schnorfeil","year":"2015","unstructured":"Schnorfeil FM, et al. T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. J Hematol Oncol. 2015;8:93.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"1795_CR11","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","volume":"9","author":"N Daver","year":"2019","unstructured":"Daver N, et al. Efficacy, safety, and biomarkers of response to Azacitidine and Nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study. Cancer Discov. 2019;9(3):370\u201383.","journal-title":"Cancer Discov"},{"key":"1795_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cells11142249","author":"Y Abaza","year":"2022","unstructured":"Abaza Y, Zeidan AM. Immune checkpoint inhibition in acute myeloid leukemia and myelodysplastic syndromes. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11142249.","journal-title":"Cells"},{"issue":"1","key":"1795_CR13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40364-023-00456-x","volume":"11","author":"H Yang","year":"2023","unstructured":"Yang H, Xun Y, You H. The landscape overview of CD47-based immunotherapy for hematological malignancies. Biomark Res. 2023;11(1):15.","journal-title":"Biomark Res"},{"issue":"4","key":"1795_CR14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11912-019-0781-7","volume":"21","author":"M Stahl","year":"2019","unstructured":"Stahl M, Goldberg AD. Immune checkpoint inhibitors in acute myeloid leukemia: novel combinations and therapeutic targets. Curr Oncol Rep. 2019;21(4):37.","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"1795_CR15","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/bloodadvances.2017014175","volume":"2","author":"PG Maslak","year":"2018","unstructured":"Maslak PG, et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv. 2018;2(3):224\u201334.","journal-title":"Blood Adv"},{"issue":"3","key":"1795_CR16","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/leu.2016.254","volume":"31","author":"MH Qazilbash","year":"2017","unstructured":"Qazilbash MH, et al. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia. 2017;31(3):697\u2013704.","journal-title":"Leukemia"},{"issue":"15","key":"1795_CR17","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2017-04-780155","volume":"130","author":"S Anguille","year":"2017","unstructured":"Anguille S, et al. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. Blood. 2017;130(15):1713\u201321.","journal-title":"Blood"},{"issue":"9","key":"1795_CR18","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1038\/s41375-023-01980-3","volume":"37","author":"Y Fl\u00f8isand","year":"2023","unstructured":"Fl\u00f8isand Y, et al. WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy. Leukemia. 2023;37(9):1842\u20139.","journal-title":"Leukemia"},{"issue":"1","key":"1795_CR19","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13045-021-01197-w","volume":"14","author":"Z Jiang","year":"2021","unstructured":"Jiang Z, et al. Targeting CD47 for cancer immunotherapy. J Hematol Oncol. 2021;14(1):180.","journal-title":"J Hematol Oncol"},{"issue":"15","key":"1795_CR20","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.22.01794","volume":"41","author":"DA Sallman","year":"2023","unstructured":"Sallman DA, et al. Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study. J Clin Oncol. 2023;41(15):2815\u201326.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1795_CR21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/14737140.2019.1589374","volume":"19","author":"JP Bewersdorf","year":"2019","unstructured":"Bewersdorf JP, Stahl M, Zeidan AM. Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled. Expert Rev Anticancer Ther. 2019;19(5):393\u2013404.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"1795_CR22","first-page":"178","volume":"21","author":"S Taghiloo","year":"2022","unstructured":"Taghiloo S, Norozi S, Asgarian-Omran H. The effects of PI3K\/Akt\/mTOR signaling pathway inhibitors on the expression of immune checkpoint ligands in acute myeloid leukemia cell line. Iran J Allergy Asthma Immunol. 2022;21(2):178\u201388.","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"1795_CR23","doi-asserted-by":"crossref","first-page":"1151032","DOI":"10.3389\/fphar.2023.1151032","volume":"14","author":"Y Chen","year":"2023","unstructured":"Chen Y, et al. A perspective of immunotherapy for acute myeloid leukemia: current advances and challenges. Front Pharmacol. 2023;14:1151032.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1795_CR24","first-page":"1","volume":"3","author":"M Farrokhi","year":"2023","unstructured":"Farrokhi M, et al. Role of precision medicine and personalized medicine in the treatment of diseases. Kindle. 2023;3(1):1\u2013164.","journal-title":"Kindle"},{"issue":"24","key":"1795_CR25","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","volume":"379","author":"MJ Christopher","year":"2018","unstructured":"Christopher MJ, et al. Immune escape of relapsed AML cells after allogeneic transplantation. N Engl J Med. 2018;379(24):2330\u201341.","journal-title":"N Engl J Med"},{"issue":"18","key":"1795_CR26","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood-2009-02-206946","volume":"114","author":"R Le Dieu","year":"2009","unstructured":"Le Dieu R, et al. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood. 2009;114(18):3909\u201316.","journal-title":"Blood"},{"issue":"1","key":"1795_CR27","doi-asserted-by":"crossref","first-page":"11697","DOI":"10.1038\/s41598-019-48256-4","volume":"9","author":"D Yoyen-Ermis","year":"2019","unstructured":"Yoyen-Ermis D, et al. Myeloid maturation potentiates STAT3-mediated atypical IFN-\u03b3 signaling and upregulation of PD-1 ligands in AML and MDS. Sci Rep. 2019;9(1):11697.","journal-title":"Sci Rep"},{"issue":"1","key":"1795_CR28","volume":"24","author":"S Huang","year":"2023","unstructured":"Huang S, et al. Higher PD-1\/Tim-3 expression on IFN-\u03b3+ T cells is associated with poor prognosis in patients with acute myeloid leukemia. Cancer Biol Ther. 2023;24(1): 2278229.","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"1795_CR29","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.immuni.2004.06.017","volume":"21","author":"T Pentcheva-Hoang","year":"2004","unstructured":"Pentcheva-Hoang T, et al. B7\u20131 and B7\u20132 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity. 2004;21(3):401\u201313.","journal-title":"Immunity"},{"issue":"2","key":"1795_CR30","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0301-472X(01)00768-8","volume":"30","author":"F Re","year":"2002","unstructured":"Re F, et al. Expression of CD86 in acute myelogenous leukemia is a marker of dendritic\/monocytic lineage. Exp Hematol. 2002;30(2):126\u201334.","journal-title":"Exp Hematol"},{"issue":"5","key":"1795_CR31","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989\u20131004.","journal-title":"Immunity"},{"key":"1795_CR32","volume":"11","author":"M Rezaei","year":"2021","unstructured":"Rezaei M, et al. TIM-3 in leukemia; immune response and beyond. Front Oncol. 2021;11: 753677.","journal-title":"Front Oncol"},{"issue":"12","key":"1795_CR33","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni1271","volume":"6","author":"C Zhu","year":"2005","unstructured":"Zhu C, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6(12):1245\u201352.","journal-title":"Nat Immunol"},{"key":"1795_CR34","first-page":"1","volume":"9","author":"OS Aval","year":"2025","unstructured":"Aval OS, et al. Galectin-9: a double-edged sword in Acute Myeloid Leukemia. Ann Hematol. 2025;9:1\u20134.","journal-title":"Ann Hematol"},{"key":"1795_CR35","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.3389\/fimmu.2018.02227","volume":"9","author":"Y Han","year":"2018","unstructured":"Han Y, et al. Acute myeloid leukemia cells express ICOS ligand to promote the expansion of regulatory T cells. Front Immunol. 2018;9:2227.","journal-title":"Front Immunol"},{"issue":"7768","key":"1795_CR36","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41586-019-1410-1","volume":"572","author":"AM Paczulla","year":"2019","unstructured":"Paczulla AM, et al. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature. 2019;572(7768):254\u20139.","journal-title":"Nature"},{"issue":"1","key":"1795_CR37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/gene.2014.58","volume":"16","author":"A Baraga\u00f1o Raneros","year":"2015","unstructured":"Baraga\u00f1o Raneros A, et al. Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia. Genes Immun. 2015;16(1):71\u201382.","journal-title":"Genes Immun"},{"issue":"5","key":"1795_CR38","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3324\/haematol.2013.087536","volume":"99","author":"K Stringaris","year":"2014","unstructured":"Stringaris K, et al. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica. 2014;99(5):836\u201347.","journal-title":"Haematologica"},{"issue":"9","key":"1795_CR39","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3324\/haematol.2010.039743","volume":"96","author":"MJ Szczepanski","year":"2011","unstructured":"Szczepanski MJ, et al. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica. 2011;96(9):1302\u20139.","journal-title":"Haematologica"},{"issue":"3","key":"1795_CR40","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/s41375-019-0585-7","volume":"34","author":"N Tumino","year":"2020","unstructured":"Tumino N, et al. PMN-MDSC are a new target to rescue graft-versus-leukemia activity of NK cells in haplo-HSC transplantation. Leukemia. 2020;34(3):932\u20137.","journal-title":"Leukemia"},{"key":"1795_CR41","first-page":"1","volume":"25","author":"A Kubaev","year":"2025","unstructured":"Kubaev A, et al. Platelet-derived extracellular vesicles: emerging players in hemostasis and thrombosis. J Liposome Res. 2025;25:1\u201311.","journal-title":"J Liposome Res"},{"issue":"7","key":"1795_CR42","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.4049\/jimmunol.160.7.3096","volume":"160","author":"M Colonna","year":"1998","unstructured":"Colonna M, et al. Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol. 1998;160(7):3096\u2013100.","journal-title":"J Immunol"},{"issue":"3","key":"1795_CR43","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1593\/neo.05703","volume":"8","author":"F Gros","year":"2006","unstructured":"Gros F, et al. Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. Neoplasia. 2006;8(3):223\u201330.","journal-title":"Neoplasia"},{"issue":"13","key":"1795_CR44","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood-2016-07-730614","volume":"129","author":"AR Pyzer","year":"2017","unstructured":"Pyzer AR, et al. MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood. 2017;129(13):1791\u2013801.","journal-title":"Blood"},{"issue":"7","key":"1795_CR45","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nm1609","volume":"13","author":"S Nagaraj","year":"2007","unstructured":"Nagaraj S, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007;13(7):828\u201335.","journal-title":"Nat Med"},{"issue":"10","key":"1795_CR46","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0167-5699(99)01520-0","volume":"20","author":"AL Mellor","year":"1999","unstructured":"Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today. 1999;20(10):469\u201373.","journal-title":"Immunol Today"},{"issue":"5","key":"1795_CR47","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s12185-015-1865-2","volume":"102","author":"H Sun","year":"2015","unstructured":"Sun H, et al. Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia. Int J Hematol. 2015;102(5):579\u201386.","journal-title":"Int J Hematol"},{"issue":"4","key":"1795_CR48","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1172\/JCI129204","volume":"130","author":"L Vago","year":"2020","unstructured":"Vago L, Gojo I. Immune escape and immunotherapy of acute myeloid leukemia. J Clin Invest. 2020;130(4):1552\u201364.","journal-title":"J Clin Invest"},{"issue":"8","key":"1795_CR49","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood-2009-03-206672","volume":"114","author":"L Zhang","year":"2009","unstructured":"Zhang L, Gajewski TF, Kline J. PD-1\/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood. 2009;114(8):1545\u201352.","journal-title":"Blood"},{"issue":"1","key":"1795_CR50","doi-asserted-by":"crossref","first-page":"12892","DOI":"10.1038\/s41598-017-12940-0","volume":"7","author":"A Mangaonkar","year":"2017","unstructured":"Mangaonkar A, et al. A novel immunohistochemical score to predict early mortality in acute myeloid leukemia patients based on indoleamine 2,3 dioxygenase expression. Sci Rep. 2017;7(1):12892.","journal-title":"Sci Rep"},{"issue":"1","key":"1795_CR51","doi-asserted-by":"crossref","first-page":"1777625","DOI":"10.1080\/2162402X.2020.1777625","volume":"9","author":"J Le Naour","year":"2020","unstructured":"Le Naour J, et al. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology. 2020;9(1):1777625.","journal-title":"Oncoimmunology"},{"key":"1795_CR52","volume":"12","author":"X Cai","year":"2021","unstructured":"Cai X, et al. Current progress and future perspectives of immune checkpoint in cancer and infectious diseases. Front Genet. 2021;12: 785153.","journal-title":"Front Genet"},{"issue":"4","key":"1795_CR53","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1795_CR54","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801.","journal-title":"Nat Commun"},{"issue":"7340","key":"1795_CR55","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/471561a","volume":"471","author":"H Ledford","year":"2011","unstructured":"Ledford H. Melanoma drug wins US approval. Nature. 2011;471(7340):561.","journal-title":"Nature"},{"issue":"4","key":"1795_CR56","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson DB, et al. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254\u201367.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"1795_CR57","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3390\/cancers11050628","volume":"11","author":"S Chr\u00e9tien","year":"2019","unstructured":"Chr\u00e9tien S, et al. Beyond PD-1\/PD-L1 inhibition: what the future holds for breast cancer immunotherapy. Cancers (Basel). 2019;11(5):628.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"1795_CR58","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.2174\/1871530321666210310142141","volume":"21","author":"M Mohsenzadegan","year":"2021","unstructured":"Mohsenzadegan M, et al. The potential of T cell immunoglobulin and mucin-domain containing-3 (Tim-3) in designing novel immunotherapy for bladder cancer. Endocr Metab Immune Disord Drug Targets. 2021;21(12):2131\u201346.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"5","key":"1795_CR59","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29(5):3044\u201360.","journal-title":"Curr Oncol"},{"issue":"4","key":"1795_CR60","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3390\/vaccines7040149","volume":"7","author":"R Saleh","year":"2019","unstructured":"Saleh R, et al. Breast cancer cells and PD-1\/PD-L1 blockade upregulate the expression of PD-1, CTLA-4, TIM-3 and LAG-3 immune checkpoints in CD4+ T cells. Vaccines. 2019;7(4):149.","journal-title":"Vaccines"},{"issue":"2","key":"1795_CR61","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3390\/jcm8020236","volume":"8","author":"K Giannopoulos","year":"2019","unstructured":"Giannopoulos K. Targeting immune signaling checkpoints in acute myeloid leukemia. J Clin Med. 2019;8(2):236.","journal-title":"J Clin Med"},{"issue":"6","key":"1795_CR62","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/07853890.2016.1186827","volume":"48","author":"P Tsirigotis","year":"2016","unstructured":"Tsirigotis P, Savani BN, Nagler A. Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies. Ann Med. 2016;48(6):428\u201339.","journal-title":"Ann Med"},{"issue":"6","key":"1795_CR63","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3390\/biomedicines11061724","volume":"11","author":"D Damiani","year":"2023","unstructured":"Damiani D, Tiribelli M. Checkpoint inhibitors in acute myeloid leukemia. Biomedicines. 2023;11(6):1724.","journal-title":"Biomedicines"},{"key":"1795_CR64","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2018.09.83","author":"A Spagnuolo","year":"2018","unstructured":"Spagnuolo A, Gridelli C. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: is there a substantial difference or not? J Thorac Dis. 2018. https:\/\/doi.org\/10.21037\/jtd.2018.09.83.","journal-title":"J Thorac Dis"},{"issue":"14","key":"1795_CR65","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3390\/cells11142249","volume":"11","author":"Y Abaza","year":"2022","unstructured":"Abaza Y, Zeidan AM. Immune checkpoint inhibition in acute myeloid leukemia and myelodysplastic syndromes. Cells. 2022;11(14):2249.","journal-title":"Cells"},{"issue":"10","key":"1795_CR66","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1111\/j.1600-6143.2012.04224.x","volume":"12","author":"LV Riella","year":"2012","unstructured":"Riella LV, et al. Role of the PD-1 pathway in the immune response. Am J Transplant. 2012;12(10):2575\u201387.","journal-title":"Am J Transplant"},{"issue":"3","key":"1795_CR67","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L. PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727.","journal-title":"Am J Cancer Res"},{"issue":"4","key":"1795_CR68","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.7150\/jca.49325","volume":"12","author":"Q Huang","year":"2021","unstructured":"Huang Q, et al. Comparative efficacy and safety of PD-1\/PD-L1 inhibitors for patients with solid tumors: a systematic review and Bayesian network meta-analysis. J Cancer. 2021;12(4):1133.","journal-title":"J Cancer"},{"key":"1795_CR69","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3389\/fphar.2019.00609","volume":"10","author":"D Liao","year":"2019","unstructured":"Liao D, et al. A review of efficacy and safety of checkpoint inhibitor for the treatment of acute myeloid leukemia. Front Pharmacol. 2019;10:609.","journal-title":"Front Pharmacol"},{"key":"1795_CR70","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.882531","volume":"12","author":"M G\u00f3mez-Llobell","year":"2022","unstructured":"G\u00f3mez-Llobell M, et al. Immune checkpoint inhibitors in acute myeloid leukemia: a meta-analysis. Front Oncol. 2022;12: 882531.","journal-title":"Front Oncol"},{"issue":"4","key":"1795_CR71","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1124\/pr.116.012682","volume":"68","author":"G Alatrash","year":"2016","unstructured":"Alatrash G, Daver N, Mittendorf EA. Targeting immune checkpoints in hematologic malignancies. Pharmacol Rev. 2016;68(4):1014\u201325.","journal-title":"Pharmacol Rev"},{"key":"1795_CR72","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00277-004-0978-0","volume":"84","author":"M Graf","year":"2005","unstructured":"Graf M, et al. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML). Ann Hematol. 2005;84:287\u201397.","journal-title":"Ann Hematol"},{"issue":"1","key":"1795_CR73","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10238-025-01588-0","volume":"25","author":"A Raoufi","year":"2025","unstructured":"Raoufi A, et al. Macrophages in graft-versus-host disease (GVHD): dual roles as therapeutic tools and targets. Clin Exp Med. 2025;25(1):73.","journal-title":"Clin Exp Med"},{"issue":"2","key":"1795_CR74","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.coi.2012.01.010","volume":"24","author":"MP Chao","year":"2012","unstructured":"Chao MP, Weissman IL, Majeti R. The CD47\u2013SIRP\u03b1 pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol. 2012;24(2):225\u201332.","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"1795_CR75","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti R, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286\u201399.","journal-title":"Cell"},{"issue":"5","key":"1795_CR76","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1083\/jcb.200708043","volume":"180","author":"RK Tsai","year":"2008","unstructured":"Tsai RK, Discher DE. Inhibition of \u201cself\u201d engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol. 2008;180(5):989\u20131003.","journal-title":"J Cell Biol"},{"issue":"63","key":"1795_CR77","first-page":"63ra94","volume":"2","author":"MP Chao","year":"2010","unstructured":"Chao MP, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med. 2010;2(63):63ra94-63ra94.","journal-title":"Sci Transl Med"},{"key":"1795_CR78","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2025.104986","volume":"414","author":"I Ahmad","year":"2025","unstructured":"Ahmad I, et al. Mesenchymal stem cell-derived exosomes (MSC-exosomes) in hematology: from mechanisms to clinical breakthroughs. Cell Immunol. 2025;414: 104986.","journal-title":"Cell Immunol"},{"issue":"9","key":"1795_CR79","volume":"10","author":"J Liu","year":"2015","unstructured":"Liu J, et al. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS ONE. 2015;10(9): e0137345.","journal-title":"PLoS ONE"},{"key":"1795_CR80","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1016\/S2152-2650(21)01337-9","volume":"21","author":"D Sallman","year":"2021","unstructured":"Sallman D, et al. Poster: AML-196: the first-in-class anti-CD47 antibody magrolimab in combination with azacitidine is well tolerated and effective in AML patients: phase 1b results. Clin Lymphoma Myeloma Leuk. 2021;21:S213.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"1795_CR81","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2024-203706","volume":"144","author":"S Arora","year":"2024","unstructured":"Arora S, et al. Phase 1b\/2 study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in patients (pts) with newly diagnosed (ND) older\/unfit or high risk acute myeloid leukemia (AML) and relapsed refractory (R\/R) AML: final clinical data and genomic markers of resistance\/relapse. Blood. 2024;144(Supplement 1):735\u2013735.","journal-title":"Blood"},{"key":"1795_CR82","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1182\/blood-2024-210370","volume":"144","author":"JM Stempel","year":"2024","unstructured":"Stempel JM, et al. Efficacy and safety of pembrolizumab added to azacitidine plus venetoclax for patients with acute myeloid leukemia: results from an investigator-initiated, multi-center, CTEP-sponsored randomized, phase II trial (BLAST AML-2). Blood. 2024;144:736.","journal-title":"Blood"},{"issue":"10","key":"1795_CR83","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2217\/imt-2020-0277","volume":"13","author":"M Wu","year":"2021","unstructured":"Wu M, et al. Therapeutic cancer vaccine therapy for acute myeloid leukemia. Immunotherapy. 2021;13(10):863\u201377.","journal-title":"Immunotherapy"},{"key":"1795_CR84","volume":"171","author":"Y Wu","year":"2024","unstructured":"Wu Y, et al. Immunotherapies of acute myeloid leukemia: rationale, clinical evidence and perspective. Biomed Pharmacother. 2024;171: 116132.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"1795_CR85","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11033-024-10200-9","volume":"52","author":"L Rajabi","year":"2025","unstructured":"Rajabi L, et al. Aqueous and ethanolic extracts of Moringa oleifera leaves induce selective cytotoxicity in Raji and Jurkat cell lines by activating the P21 pathway independent of P53. Mol Biol Rep. 2025;52(1):102.","journal-title":"Mol Biol Rep"},{"key":"1795_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14122994","author":"K Barbullushi","year":"2022","unstructured":"Barbullushi K, et al. Vaccination therapy for acute myeloid leukemia: where do we stand? Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14122994.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1795_CR87","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1182\/blood-2007-07-099366","volume":"111","author":"M Schmitt","year":"2008","unstructured":"Schmitt M, et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood. 2008;111(3):1357\u201365.","journal-title":"Blood"},{"key":"1795_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/ph16070932","author":"M Kim","year":"2023","unstructured":"Kim M, Savsani K, Dakshanamurthy S. A peptide vaccine design targeting KIT mutations in acute myeloid leukemia. Pharmaceuticals (Basel). 2023. https:\/\/doi.org\/10.3390\/ph16070932.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"1795_CR89","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/ajh.24014","volume":"90","author":"J Brayer","year":"2015","unstructured":"Brayer J, et al. WT1 vaccination in AML and MDS: a pilot trial with synthetic analog peptides. Am J Hematol. 2015;90(7):602\u20137.","journal-title":"Am J Hematol"},{"issue":"2","key":"1795_CR90","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood-2009-10-250993","volume":"116","author":"PG Maslak","year":"2010","unstructured":"Maslak PG, et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood. 2010;116(2):171\u20139.","journal-title":"Blood"},{"issue":"7","key":"1795_CR91","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2009.014704","volume":"95","author":"G Jochen","year":"2010","unstructured":"Jochen G, et al. High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica. 2010;95(7):1191\u20137.","journal-title":"Haematologica"},{"issue":"2","key":"1795_CR92","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00262-010-0929-7","volume":"60","author":"J Kuball","year":"2011","unstructured":"Kuball J, et al. Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909. Cancer Immunol Immunother. 2011;60(2):161\u201371.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"1795_CR93","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jcyt.2024.02.009","volume":"26","author":"J Motallebzadeh Khanmiri","year":"2024","unstructured":"Motallebzadeh Khanmiri J, et al. Dendritic cell vaccination strategy for the treatment of acute myeloid leukemia: a systematic review. Cytotherapy. 2024;26(5):427\u201335.","journal-title":"Cytotherapy"},{"key":"1795_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12020165","author":"F Palomares","year":"2024","unstructured":"Palomares F, et al. Dendritic cells as a therapeutic strategy in acute myeloid leukemia: vaccines. Vaccines. 2024. https:\/\/doi.org\/10.3390\/vaccines12020165.","journal-title":"Vaccines"},{"issue":"10","key":"1795_CR95","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1080\/21645515.2021.1943991","volume":"17","author":"P Chevallier","year":"2021","unstructured":"Chevallier P, et al. A phase I\/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients. Hum Vaccin Immunother. 2021;17(10):3511\u20134.","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"1795_CR96","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1159\/000512452","volume":"47","author":"DC Amberger","year":"2020","unstructured":"Amberger DC, Schmetzer HM. Dendritic cells of leukemic origin: specialized antigen-presenting cells as potential treatment tools for patients with myeloid leukemia. Transfus Med Hemother. 2020;47(6):432\u201343.","journal-title":"Transfus Med Hemother"},{"issue":"6","key":"1795_CR97","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s12032-025-02742-0","volume":"42","author":"MJ Saadh","year":"2025","unstructured":"Saadh MJ, et al. Mesenchymal stem cell-derived exosomes: a novel therapeutic frontier in hematological disorders. Med Oncol. 2025;42(6):199.","journal-title":"Med Oncol"},{"issue":"3","key":"1795_CR98","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1117","volume":"9","author":"FS Lichtenegger","year":"2020","unstructured":"Lichtenegger FS, et al. Toll-like receptor 7\/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial. Clin Transl Immunol. 2020;9(3): e1117.","journal-title":"Clin Transl Immunol"},{"issue":"3","key":"1795_CR99","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/1744-9987.13828","volume":"26","author":"M Ogasawara","year":"2022","unstructured":"Ogasawara M, et al. Wilms\u2019 tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory acute leukemia. Ther Apher Dial. 2022;26(3):537\u201347.","journal-title":"Ther Apher Dial"},{"issue":"16","key":"1795_CR100","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1002\/cncr.30696","volume":"123","author":"HJ Khoury","year":"2017","unstructured":"Khoury HJ, et al. Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia. Cancer. 2017;123(16):3061\u201372.","journal-title":"Cancer"},{"issue":"12","key":"1795_CR101","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.bbmt.2016.08.028","volume":"22","author":"NN Shah","year":"2016","unstructured":"Shah NN, et al. Induction of immune response after allogeneic Wilms\u2019 tumor 1 dendritic cell vaccination and donor lymphocyte infusion in patients with hematologic malignancies and post-transplantation relapse. Biol Blood Marrow Transplant. 2016;22(12):2149\u201354.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1795_CR102","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00262-018-2198-9","volume":"67","author":"AA van de Loosdrecht","year":"2018","unstructured":"van de Loosdrecht AA, et al. A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia. Cancer Immunol Immunother. 2018;67:1505\u201318.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"1795_CR103","first-page":"28","volume":"11","author":"A Noroozi Aghide","year":"2016","unstructured":"Noroozi Aghide A, Soleimani Samarkhazan H, Ahmadnezhad M. Effect of harmine alkaloid on the expression of P16 and DAPK in HL60 leukemia cell line. Paramed Sci Military Health. 2016;11(3):28\u201333.","journal-title":"Paramed Sci Military Health"},{"issue":"368","key":"1795_CR104","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag1298","volume":"8","author":"J Rosenblatt","year":"2016","unstructured":"Rosenblatt J, et al. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci Transl Med. 2016;8(368): 368ra171-368ra171.","journal-title":"Sci Transl Med"},{"key":"1795_CR105","doi-asserted-by":"crossref","first-page":"1108200","DOI":"10.3389\/fimmu.2023.1108200","volume":"14","author":"B Aru","year":"2023","unstructured":"Aru B, et al. A potential area of use for immune checkpoint inhibitors: targeting bone marrow microenvironment in acute myeloid leukemia. Front Immunol. 2023;14:1108200.","journal-title":"Front Immunol"},{"issue":"7","key":"1795_CR106","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s12032-025-02787-1","volume":"42","author":"SO Rab","year":"2025","unstructured":"Rab SO, et al. Targeting platelet-tumor cell interactions: a novel approach to cancer therapy. Med Oncol. 2025;42(7):232.","journal-title":"Med Oncol"},{"issue":"1","key":"1795_CR107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12094-019-02132-9","volume":"22","author":"M Maleknia","year":"2020","unstructured":"Maleknia M, et al. Immunomodulation in leukemia: cellular aspects of anti-leukemic properties. Clin Transl Oncol. 2020;22(1):1\u201310.","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"1795_CR108","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-020-01069-1","volume":"35","author":"R Nair","year":"2021","unstructured":"Nair R, Salinas-Illarena A, Baldauf HM. New strategies to treat AML: novel insights into AML survival pathways and combination therapies. Leukemia. 2021;35(2):299\u2013311.","journal-title":"Leukemia"},{"issue":"2","key":"1795_CR109","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bjh.17746","volume":"196","author":"S Kayser","year":"2022","unstructured":"Kayser S, Levis MJ. Updates on targeted therapies for acute myeloid leukaemia. Br J Haematol. 2022;196(2):316\u201328.","journal-title":"Br J Haematol"},{"issue":"14","key":"1795_CR110","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1080\/10428194.2019.1630622","volume":"60","author":"S Shahrabi","year":"2019","unstructured":"Shahrabi S, et al. Neutropenia and leukemia development: genetic risk factors and prognosis. Leuk Lymphoma. 2019;60(14):3363\u201374.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"1795_CR111","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018925","volume":"6","author":"S Catellani","year":"2011","unstructured":"Catellani S, et al. Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia. PLoS ONE. 2011;6(4): e18925.","journal-title":"PLoS ONE"},{"issue":"12","key":"1795_CR112","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"3","key":"1795_CR113","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm.4484","volume":"24","author":"NR Mathew","year":"2018","unstructured":"Mathew NR, et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018;24(3):282\u201391.","journal-title":"Nat Med"},{"issue":"2","key":"1795_CR114","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","volume":"111","author":"H Kiyoi","year":"2020","unstructured":"Kiyoi H, Kawashima N, Ishikawa Y. FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development. Cancer Sci. 2020;111(2):312\u201322.","journal-title":"Cancer Sci"},{"issue":"6","key":"1795_CR115","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/bloodadvances.2019000174","volume":"4","author":"M Levis","year":"2020","unstructured":"Levis M, Perl AE. Gilteritinib: potent targeting of FLT3 mutations in AML. Blood Adv. 2020;4(6):1178\u201391.","journal-title":"Blood Adv"},{"issue":"13","key":"1795_CR116","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.23.01911","volume":"42","author":"NJ Short","year":"2024","unstructured":"Short NJ, et al. Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML. J Clin Oncol. 2024;42(13):1499\u2013508.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1795_CR117","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bjh.19096","volume":"203","author":"M Donnette","year":"2023","unstructured":"Donnette M, et al. Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients. Br J Haematol. 2023;203(4):625\u201336.","journal-title":"Br J Haematol"},{"key":"1795_CR118","doi-asserted-by":"crossref","unstructured":"IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021. J Adv Pract Oncol. 2022;13(Suppl 1): 12\u201314","DOI":"10.6004\/jadpro.2022.13.1.11"},{"issue":"10","key":"1795_CR119","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1038\/s41375-023-02001-z","volume":"37","author":"MA Sekeres","year":"2023","unstructured":"Sekeres MA, et al. Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial. Leukemia. 2023;37(10):2017\u201326.","journal-title":"Leukemia"},{"key":"1795_CR120","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164121","author":"F Tarantini","year":"2021","unstructured":"Tarantini F, et al. Can the new and old drugs exert an immunomodulatory effect in acute myeloid leukemia? Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13164121.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"1795_CR121","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41375-021-01425-9","volume":"36","author":"C R\u00e9cher","year":"2022","unstructured":"R\u00e9cher C, et al. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. Leukemia. 2022;36(4):913\u201322.","journal-title":"Leukemia"},{"issue":"1","key":"1795_CR122","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-021-01062-w","volume":"14","author":"H Liu","year":"2021","unstructured":"Liu H. Emerging agents and regimens for AML. J Hematol Oncol. 2021;14(1):49.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1795_CR123","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40364-025-00786-y","volume":"13","author":"S Zehtabcheh","year":"2025","unstructured":"Zehtabcheh S, et al. Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies. Biomark Res. 2025;13(1):73.","journal-title":"Biomark Res"},{"issue":"1","key":"1795_CR124","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7\u201317.","journal-title":"Blood"},{"issue":"5","key":"1795_CR125","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41375-018-0070-8","volume":"32","author":"N Daver","year":"2018","unstructured":"Daver N, et al. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 2018;32(5):1094\u2013105.","journal-title":"Leukemia"},{"issue":"Supplement_1","key":"1795_CR126","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1182\/blood-2019-127345","volume":"134","author":"I Gojo","year":"2019","unstructured":"Gojo I, et al. Multi-center phase 2 study of Pembroluzimab (Pembro) and Azacitidine (AZA) in patients with relapsed\/refractory acute myeloid leukemia (AML) and in newly diagnosed (\u226565 years) AML patients. Blood. 2019;134(Supplement_1):832\u2013832.","journal-title":"Blood"},{"key":"1795_CR127","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312919","author":"F Brauneck","year":"2021","unstructured":"Brauneck F, et al. Combined blockade of TIGIT and CD39 or A2AR enhances NK-92 cell-mediated cytotoxicity in AML. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222312919.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1795_CR128","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1309\/LMTDDRGLY374WSCQ","volume":"39","author":"MP Chao","year":"2008","unstructured":"Chao MP, Weissman IL, Park CY. Cancer stem cells: on the verge of clinical translation. Lab Med. 2008;39(11):679\u201386.","journal-title":"Lab Med"},{"key":"1795_CR129","unstructured":"Vyas PK, Kelly R, Salim R, Lubowiecki M, Royston D, Johnson H, Roberts C, Chen J, Agoram B, et al. Initial phase 1 results of the first-in-class anti-Cd47 antibody Hu5f9-G4 in relapsed\/refractory acute myeloid leukemia patients. 2018"},{"issue":"15_suppl","key":"1795_CR130","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1200\/JCO.2020.38.15_suppl.7507","volume":"38","author":"DA Sallman","year":"2020","unstructured":"Sallman DA, et al. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: phase Ib results. J Clin Oncol. 2020;38(15_suppl):7507\u20137507.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1795_CR131","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7150\/jca.13674","volume":"7","author":"X Song","year":"2016","unstructured":"Song X, et al. Microrna-874 functions as a tumor suppressor by targeting cancer\/testis antigen HCA587\/MAGE-C2. J Cancer. 2016;7(6):656\u201363.","journal-title":"J Cancer"},{"issue":"10","key":"1795_CR132","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00262-018-2198-9","volume":"67","author":"AA van de Loosdrecht","year":"2018","unstructured":"van de Loosdrecht AA, et al. A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia. Cancer Immunol Immunother. 2018;67(10):1505\u201318.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"1795_CR133","volume":"29","author":"Y Gao","year":"2024","unstructured":"Gao Y, et al. VISTA: a novel checkpoint for cancer immunotherapy. Drug Discov Today. 2024;29(7): 104045.","journal-title":"Drug Discov Today"},{"issue":"1","key":"1795_CR134","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12935-023-03116-0","volume":"23","author":"N Shekari","year":"2023","unstructured":"Shekari N, et al. VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy. Cancer Cell Int. 2023;23(1):265.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"1795_CR135","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40364-025-00738-6","volume":"13","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. Unveiling the potential of CLL-1: a promising target for AML therapy. Biomark Res. 2025;13(1):28.","journal-title":"Biomark Res"},{"issue":"1","key":"1795_CR136","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s11033-025-10527-x","volume":"52","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. C-type lectin-like molecule-1 as a diagnostic, prognostic, and therapeutic marker in leukemia. Mol Biol Rep. 2025;52(1):464.","journal-title":"Mol Biol Rep"},{"issue":"1","key":"1795_CR137","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s10238-025-01686-z","volume":"25","author":"AK Bishoyi","year":"2025","unstructured":"Bishoyi AK, et al. Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation. Clin Exp Med. 2025;25(1):166.","journal-title":"Clin Exp Med"},{"issue":"1","key":"1795_CR138","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s10238-025-01724-w","volume":"25","author":"A Bayani","year":"2025","unstructured":"Bayani A, et al. Aptamer-based approaches in leukemia: a paradigm shift in targeted therapy. Clin Exp Med. 2025;25(1):186.","journal-title":"Clin Exp Med"},{"issue":"1","key":"1795_CR139","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11033-025-10692-z","volume":"52","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. Curcumin and acute myeloid leukemia: a golden hope, updated insights. Mol Biol Rep. 2025;52(1):583.","journal-title":"Mol Biol Rep"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01795-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01795-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01795-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:47:12Z","timestamp":1764917232000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01795-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":139,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1795"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01795-9","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"240"}}